OmantaYC S26 landing page report.
← Back to YC S26
Omantahttps://omanta.com/

Your landing page’s weakest score is Trust.

How Omanta ranks

  1. 1.The Institute for Follicular Lymphoma Innovation (Private Medical-style N-of-1 r68
  2. 2.Perlara60
  3. 3.Omanta53
  4. 4.Every Cure46
Fix Trust
53Growth scoreupdated

category scores

Trust34CTA48Value props48Mobile web62Information hierarchy72
category scoresShowHide
Trust34CTA48Value props48Mobile web62Information hierarchy72

Score over time

807060504030Perlara 39 on Apr 7 (Wayback)Perlara 39 on May 10 (Wayback)Perlara 62 on Jun 10 (Wayback)Perlara 61 on Jun 17 (Wayback)Perlara 59 on Jul 26 (Wayback)Perlara 60 on Sep 20 (Live)Every Cure 57 on May 19 (Wayback)Every Cure 54 on Jun 11 (Wayback)Every Cure 55 on Jun 19 (Wayback)Every Cure 55 on Jul 11 (Wayback)Every Cure 56 on Jul 21 (Wayback)Every Cure 56 on Aug 31 (Wayback)Every Cure 46 on Sep 20 (Live)The Institute for Follicular Lymphoma Innovation (Private Medical-style N-of-1 r 68 on Sep 20 (Live)Omanta 54 on Aug 6 (Wayback)Omanta 54 on Aug 18 (Wayback)Omanta 53 on Sep 20 (Live)Aug 6Aug 18Sep 20
Past reportsShow past reportsHide past reports
  1. Sep 20, 202653LiveOverall −1 · CTA −10 · Information hierarchy +6Viewing
  2. Aug 18, 202654CTA +10 · Information hierarchy −6View →
  3. Aug 6, 202654First tracked report — strongest Information hierarchy 72, weakest Trust 42View →

Trust

34Poor

Proof that the product is real, competent, and safe to try.

The Institute for Follicular Lymphoma Innovation (Private Medical-style N-of-1 r
Perlara
Every Cure
Trust read
OmantaNo visible trust signal identified.
PerlaraSpecific disease-area copy: "congenital disorders of glycosylation, mitochondrial disorders, GPI-anchor defects, tRNA-sy
Every CurePhotograph of a clinician consulting with a hospital patient behind the hero headline
The Institute for Follicular Lymphoma Innovation (Private Medical-style N-of-1 r"Helping thousands of families and trusted by 100+ patient communities"

CTA

48Poor

Copy, size, verb, cost-feel — does the primary CTA earn the click?

Omanta
Perlara
The Institute for Follicular Lymphoma Innovation (Private Medical-style N-of-1 r

Problems

  • nav link, no hero button
  • tiny vs. huge headline
  • 'conversation' feels committal
  • invisible in mobile hero

Value props

48Poor

Title, subtitle, hero — do they sell the product's true value?

Omanta’s headline vagueA research lab For One.Built around your options. And what comes next.

Working

  • "For One" signals deep personalization
  • Emotionally resonant, human tone
  • Distinctive, memorable phrasing

Could improve

  • Never says what Omanta actually does
  • No concrete outcome or deliverable
  • Hero art decorates, demonstrates nothing

Mobile web

62Fair

The phone experience as a first-class citizen.

Mobile web annotations on the mobile capture12
  1. Begin a conversation link — The only CTA is a small, unstyled text link in the header — too small to tap and easy to miss.
  2. Collapsed nav row — Approach, For Clinicians, and Leadership links vanish on mobile with no hamburger to reach them.

Information hierarchy

72Fair

Does the design help or inhibit what the page is trying to say?

Information hierarchy annotations on the desktop capture123
  1. Begin a conversation link — Primary CTA rendered as plain nav text, same weight as the three exit links beside it.
  2. Nav link row — 'Approach', 'For Clinicians', 'Leadership' sit at equal weight with the CTA, leaking attention before action.
  3. Subhead 'Built around Omanta's options.' — Three-line, mixed-size stack reads as fragments and mismatches mobile's 'Built around Omanta.'

Competitors

inferred from product, audience, and value prop
#1The Institute for Follicular Lymphoma Innovation (Private Medical-style N-of-1 rciitizen.com68 #2Perlaraperlara.com60
#3Omanta53
#4Every Cureeverycure.org46